Search
01/03/2023
HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS
Cordero, A, Munoz-Garcia, N, Padro, T, Vilahur, G, Bertomeu-Gonzalez, V, Escribano, D, Flores, E, Zuazola, P, Badimon, L. HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(6)DOI:10.3390/ijms24065391. PMID:36982465. IF:4.900(Q1/3D).
01/03/2023
Essential protein P116 extracts cholesterol and other indispensable lipids for Mycoplasmas
Sprankel L., Vizarraga D., Martín J., Manger S., Meier-Credo J., Marcos M., Julve J., Rotllan N., Scheffer M.P., Escolà-Gil J.C., Langer J.D., Piñol J., Fita I., Frangakis A.S.. Essential protein P116 extracts cholesterol and other indispensable lipids for Mycoplasmas. NATURE STRUCTURAL & MOLECULAR BIOLOGY. 2023; 30(3)DOI:10.1038/s41594-023-00922-y. PMID:36782049. IF:12.500(Q1/1D).
01/03/2023
Caffeine and the Risk of Diabetic Retinopathy in Type 2 Diabetes Mellitus: Findings from Clinical and Experimental Studies
Alcubierre, N, Granado-Casas, M, Bogdanov, P, Hernandez, C, Ramos, H, Castelblanco, E, Real, J, Rubinat-Arnaldo, E, Traveset, A, Hernandez, M, Jurjo, C, Vioque, J, Navarrete-Munoz, EM, Simo, R, Mauricio, D. Caffeine and the Risk of Diabetic Retinopathy in Type 2 Diabetes Mellitus: Findings from Clinical and Experimental Studies. Nutrients. 2023; 15(5)DOI:10.3390/nu15051169. PMID:36904168. IF:4.800(Q1/2D).
01/03/2023
Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
Rodriguez-Calvo, R, Granado-Casas, M, de Oca, APM, Julian, MT, Domingo, M, Codina, P, Santiago-Vacas, E, Cediel, G, Julve, J, Rossell, J, Masana, L, Mauricio, D, Lupon, J, Bayes-Genis, A, Alonso, N. Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus. Antioxidants. 2023; 12(3)DOI:10.3390/antiox12030645. PMID:36978893. IF:6.000(Q1/2D).
01/03/2023
Circulating metabolomic and lipidomic changes in subjects with new-onset type 1 diabetes after optimization of glycemic control
Julve, J, Genua, I, Quifer-Rada, P, Yanes, O, Barranco-Altirriba, M, Hernandez, M, Junza, A, Capellades, J, Granado-Casas, M, Alonso, N, Castelblanco, E, Mauricio, D. Circulating metabolomic and lipidomic changes in subjects with new-onset type 1 diabetes after optimization of glycemic control. DIABETES RESEARCH AND CLINICAL PRACTICE. 2023; 197DOI:10.1016/j.diabres.2023.110578. PMID:36804334. IF:6.100(Q1/2D).
01/03/2023
Living with gout. Experiences, impact and challenges of the disease. Qualitative study through focus groups
Díaz-Torné C., Pou M.A., Rodríguez-Díez B., Pujol-Ribera E.. Living with gout. Experiences, impact and challenges of the disease. Qualitative study through focus groups. Reumatologia Clinica. 2023; 19(3)DOI:10.1016/j.reuma.2022.03.009. PMID:36058814. IF:(Q/D).
01/03/2023
What's New in the 2022 Consensus for Severe Asthma in Adults.
Alvarez-Gutiérrez FJ, Blanco-Aparicio M, Casas-Maldonado F, Plaza V, González-Barcala FJ, Carretero-Gracia JÁ, Castilla-Martínez M, Cisneros C, Diaz-Pérez D, Domingo-Ribas C, Martínez-Moragon E, Muñoz X, Padilla-Galo A, Perpiña-Tordera M, Soto-Campos G. What's New in the 2022 Consensus for Severe Asthma in Adults.. ARCHIVOS DE BRONCONEUMOLOGIA. 2023; 59(3)DOI:10.1016/j.arbres.2022.09.012. PMID:36243640. IF:8.700(Q1/1D).
01/03/2023
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
Waters, L, Assoumou, L, Gonzalez-Cordon, A, Rusconi, S, Domingo, P, Gompels, M, de Wit, S, Raffi, F, Stephan, C, Masia, M, Rockstroh, J, Katlama, C, Behrens, GMN, Moyle, G, Johnson, M, Fox, J, Stellbrink, HJ, Guaraldi, G, Florence, E, Esser, S, Gatell, JM, Pozniak, A, Martinez, E. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. CLINICAL INFECTIOUS DISEASES. 2023; 76(5)DOI:10.1093/cid/ciac827. PMID:36259527. IF:8.200(Q1/1D).